Cellebrite insider plans sale of 1,165 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
David Gee, a shareholder of Cellebrite DI Ltd., filed a notice of proposed sale under Rule 144 to sell 1,165 ordinary shares (par value NIS 0.00001), with an aggregate market value of $16,612.90, through Morgan Stanley Smith Barney on or about February 12, 2026.
The filing notes that these securities relate to restricted share units that vested on February 12, 2026 under an issuer S-8 registered plan, with 2,618 shares acquired as employee compensation. The notice also reports prior sales in the last three months totaling 3,704 shares for $63,121.53 and 1,969 shares for $33,236.72, and states that 248,830,759 ordinary shares were outstanding. Gee represents that he is not aware of undisclosed material adverse information about Cellebrite.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Form 144 filing for Cellebrite (CLBT) disclose?
What representation does the seller make about Cellebrite (CLBT) information in this Form 144?
AI-generated analysis. How Rhea-AI works. Not financial advice.